Introduction: The Global Tacrolimus Trade Landscape Tacrolimus (FK506) is a macrolide immunosuppressant produced by Streptomyces tsukubaensis and is listed on the WHO Model List of Essential Medicines. As the cornerstone calcineurin inhibitor for preventing organ rejection after kidney, liver, and heart transplantation, tacrolimus generates substantial global trade volume. The market was valued at approximately $7.39 billion in 2026 and is projected to reach $9.06 billion by 2030, growing at a CAGR of 5.2%. For suppliers, distributors, and procurement professionals, understanding the global tacrolimus buyers list is essential for identifying new business opportunities, navigating regulatory requirements, and building resilient supply chains. Market Overview: Why Tacrolimus Demand Keeps Growing The tacrolimus market…